Positioning gestrinone among the progestins: a narrative review of pharmacology, efficacy, safety, and tolerability

Jacobsen L, Leonardo Jacobsen
Expert opinion on pharmacotherapy · 2026 · pp. 1–16 · doi:10.1080/14656566.2026.2749635 · PMID:42878410 · W7222013413
Review OA: closed public-domain-us
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-19 ⓘ

This narrative review evaluates gestrinone, a progestin used for endometriosis, finding it effective in pain management with an androgenic profile comparable to danazol but lacking direct comparisons with dienogest.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: Gestrinone is an androgenic progestin derived from 19-nortestosterone, in use for four decades in endometriosis and other estrogen-dependent conditions. It has largely disappeared from contemporary progestin taxonomies and is sometimes described as an anabolic-androgenic steroid. This review examines its pharmacology and the evidence for its use. AREAS COVERED: Narrative review without a prespecified protocol, based on searches of PubMed, trial registries and regulatory sources, without date or language limits. It integrates chemistry and multireceptor pharmacology, pharmacokinetics, comparative efficacy against danazol, gonadotropin-releasing hormone (GnRH) agonists and other progestins, and safety, by indication, route and formulation. EXPERT OPINION: Gestrinone was active in every controlled setting tested, and the direct comparisons against danazol and a GnRH agonist detected no difference in the principal pain outcomes, in trials too small to establish equivalence; no direct comparison with dienogest exists. Its hallmark is an androgenic-metabolic signature, and its androgenic effects are not consistently milder than those of danazol. Skeletal findings varied between studies and doses and do not establish long-term protection or the absence of a need for add-back therapy. Priorities are formulation-specific exposure data and contemporary comparisons.

My notes (saved in your browser only)

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (73)

SciLite annotations

chemicals 14
gestrinone progestin gestrinone progestin 19-oxotestosterone estrogen progestin steroid danazol progestin gestrinone danazol dienogest danazol

Source provenance

europepmc
last seen: 2026-10-26T06:15:05.866214+00:00
openalex
last seen: 2026-10-26T06:07:52.047309+00:00
pubmed
last seen: 2026-10-26T06:09:31.814270+00:00
scilite
last seen: 2026-10-25T10:06:56.708568+00:00
unpaywall
last seen: 2026-10-26T06:31:53.434635+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine